MedTrace Logo

Vitamin D Supplementation in Patients With Depression

NCT03766074 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-12-13

No results posted yet for this study

Summary

Groups (intervention group receives 50000 IU vitamin D and control group receives placebo) through a random allocation. After 8 weeks, blood sample will be collected from each participant. The studied indices (inflammatory (IL-1β, IL-6, hs-CRP), PTH, platelet serotonin, serum oxytocin, serum 25(OH) D, depression status and anthropometry indices) will be evaluated at beginning and end of interventional period.

Conditions

Interventions

DIETARY_SUPPLEMENT

vitamin D supplement

The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.

DIETARY_SUPPLEMENT

Placebo

placebo

Sponsors & Collaborators

  • Tirang R. Neyestani, Ph.D.

    lead OTHER

Principal Investigators

  • Tirang R. Neyestani, Ph.D · National Nutrition and Food Technology Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-06
Primary Completion
2019-04-30
Completion
2019-09-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03766074 on ClinicalTrials.gov